Estrogen-progestin oral contraceptive and nicotine exposure synergistically confers cardio-renoprotection in female Wistar rats
No Thumbnail Available
Date
2020-06-07
Authors
Michael, Olugbenga Samuel
Dibia, Chinaza
Adeyanju, Oluwaseun
Olaniyi, Kehinde
Areola, Emmanuel
Olatunji, Lawrence Aderemi
Journal Title
Journal ISSN
Volume Title
Publisher
Elsevier
Abstract
Approximately fifty percent of premenopausal women who smoke cigarettes or on nicotine replacement therapy
are also on hormonal contraceptives, especially oral estrogen-progestin. Oral estrogen-progestin therapy has
been reported to promote insulin resistance (IR) which causes lipid influx into non-adipose tissue and impairs
Na+/K+ -ATPase activity, especially in the heart and kidney. However, the effects of nicotine on excess lipid and
altered Na+/K+ -ATPase activity associated with the use of estrogen-progestin therapy have not been fully
elucidated. This study therefore aimed at investigating the effect of nicotine on cardiac and renal lipid influx and
Na+/K+ -ATPase activity during estrogen-progestin therapy. Twenty-four female Wistar rats grouped into 4
(n = 6/group) received (p.o.) vehicle, nicotine (1.0 mg/kg) with or without estrogen-progestin steroids (1.0 μg ethinyl estradiol and 5.0 μg levonorgestrel) and estrogen-progestin only daily for 6 weeks. Data showed that estrogen-progestin treatment or nicotine exposure caused IR, hyperinsulinemia, increased cardiac and renal uric acid, malondialdehyde, triglyceride, glycogen synthase kinase-3, plasminogen activator inhibitor-1, reduced bilirubin and circulating estradiol. Estrogen-progestin treatment led to decreased cardiac Na+/K+-ATPase ac tivity while nicotine did not alter Na+/K+-ATPase activity but increased plasma and tissue cotinine. Renal Na+/K+-ATPase activity was not altered by the treatments. However, all these alterations were reversed following combined administration of oral estrogen-progestin therapy and nicotine. The present study therefore demon strates that oral estrogen-progestin therapy and nicotine exposure synergistically prevents IR-linked cardio-renotoxicity with corresponding improvement in cardiac and renal lipid accumulation, oxidative stress, in-
flammation and Na+/K+-ATPase activity
Description
Keywords
Estrogen-progestin therapy, Cardiac, Na+-K+-ATPase activity, Lipid, Insulin resistance, Metabolic stress, Nicotine
Citation
10.Michael, O.S., Dibia, C.L., Adeyanju, O.A., Olaniyi, K.S., Areola, E.D., & Olatunji, L.A. (2020). Estrogen-progestin oral contraceptive and nicotine exposure synergistically confers cardio-renoprotection in female Wistar rats. Biomedicine and Pharmacotherapy, 129, 110387, Published by Elsevier. Available online at: Biomedicine & Pharmacotherapy | Vol 129, September 2020 | ScienceDirect.com by Elsevier